Australia vs Belarus: Statin use vs. average non-HDL cholesterol levels
Australia
3.2
in 2018
Belarus
3.2
in 2018
Australia rank
118th
Belarus rank
118th
Statin use vs. average non-HDL cholesterol levels over time
- Australia
- Belarus
How they compare
Australia currently reports 3.2 against 3.2 in Belarus, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Australia ahead.
Australia ranks 118th and Belarus ranks 118th of 191 countries.
Across the 4 decades both report, Australia averaged higher in 3 and Belarus in 1.
Head to head by decade
| Decade | Australia | Belarus | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.2 | 4 | 0.2 | Australia |
| 1990s | 4.06 | 3.92 | 0.14 | Australia |
| 2000s | 3.7 | 3.69 | 0.01 | Australia |
| 2010s | 3.36 | 3.39 | 0.0333 | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Australia or Belarus?
- Australia, at 3.2 against 3.2 in Belarus as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Australia and Belarus?
- 0, with Australia ahead.
- How many years of comparable data are there for Australia and Belarus?
- 39 years are reported by both, from 1980 to 2018.
- How do Australia and Belarus rank globally for statin use vs. average non-hdl cholesterol levels?
- Australia ranks 118th and Belarus ranks 118th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.